Venture capital investment in new medical technologies has reached all-time highs, with more than $25 billion invested in biopharmaceutical, medical device, and diagnostics startups in 2018.1 However, what exact effect this has had on the clinical practice of oncology and on determining which therapies are available to patients is unclear. From 2010 to 2017, venture capital deal valuation in US biopharma companies increased by 139% to $10.5 billion and that of venture capital deals in US device companies increased by 61% to $5.0 billion.2 Given the role of venture capital in financing medical innovations, oncologists and policy makers should understand the basics of venture capital, including how venture capitalists decide on investments, the potential risk-benefit effect on patients, and the implications for how new therapeutics, diagnostics, and devices enter practice.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Huang KB, Nambudiri VE. How Is Money Changing Medicine?—Venture Capital Investment in Oncology. JAMA Oncol. Published online January 02, 2020. doi:10.1001/jamaoncol.2019.5348
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: